Xuanzhu Biopharmaceutical Co (HKSE:02575) Total Equity: HK$1,513.75 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02575 Xuanzhu Biopharmaceutical Co Ltd HKSE:02575
11 GF Score
Price HK$12.88
! 1 Warning Sign
View Full Analysis

What is Xuanzhu Biopharmaceutical Co Total Equity?

Xuanzhu Biopharmaceutical Co HKSE:02575 +3.21% 11 Total Equity is HK$1,513.75 Mil as of Dec. 2025. GuruFocus rates HKSE:02575 with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Xuanzhu Biopharmaceutical Co's total equity for the quarter that ended in Dec. 2025 was HK$1,513.75 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Xuanzhu Biopharmaceutical Co Total Equity Historical Data

* Premium members only.

The historical data trend for Xuanzhu Biopharmaceutical Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xuanzhu Biopharmaceutical Co Total Equity Chart

Xuanzhu Biopharmaceutical Co Annual Data
Trend Dec23 Dec24 Dec25
Total Equity
1,214.37 1,021.46 1,513.75

Xuanzhu Biopharmaceutical Co Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity 1,214.37 0.00 1,021.46 924.52 1,513.75
HKSE:02575
11GF Score
Xuanzhu Biopharmaceutical Co Ltd HKSE:02575
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xuanzhu Biopharmaceutical Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Xuanzhu Biopharmaceutical Co's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1812.13-298.376
=1,513.75

Xuanzhu Biopharmaceutical Co's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1812.13-298.376
=1,513.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of HK$1,513.75 Mil mean?
Xuanzhu Biopharmaceutical Co (HKSE:02575) has a Total Equity of HK$1,513.75 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Xuanzhu Biopharmaceutical Co and its competitors.
Is Xuanzhu Biopharmaceutical Co's Total Equity too high?
Xuanzhu Biopharmaceutical Co's current Total Equity is HK$1,513.75 Mil. Overall, Xuanzhu Biopharmaceutical Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Xuanzhu Biopharmaceutical Co's Total Equity compare to ZTS?
Xuanzhu Biopharmaceutical Co's Total Equity of HK$1,513.75 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Xuanzhu Biopharmaceutical Co and its competitors. Xuanzhu Biopharmaceutical Co's current Total Equity is HK$1,513.75 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xuanzhu Biopharmaceutical Co stock overvalued right now?
Xuanzhu Biopharmaceutical Co (HKSE:02575) has a current Total Equity of HK$1,513.75 Mil. The current Total Equity is HK$1,513.75 Mil. Xuanzhu Biopharmaceutical Co's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Xuanzhu Biopharmaceutical Co (HKSE:02575), the current Total Equity is HK$1,513.75 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Xuanzhu Biopharmaceutical Co Business Description

Address Zhubang 2000 Business Center, 2107, Building 2, Balizhuang Xili, Chaoyang District, Beijing, CHN
Xuanzhu Biopharmaceutical Co Ltd is an innovation-driven biopharmaceutical company in China, leveraging its understanding of China's pharmaceutical industry and insights of its clinical needs to improve patient health and life. It has over ten drug assets under active development covering digestive diseases, oncology, and NASH. Its track record also includes the successful development of four drug candidates that were subsequently transferred and/or out-licensed to pharmaceutical companies. Its pipeline is staggered and complementary in structure, covering both validated targets with druggability as well as new mechanisms of action and drug modalities, established therapeutic areas such as oncology, and high-growth potential therapeutic areas such as NASH.
11GF Score

Get the complete analysis for HKSE:02575

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$12.88
Price